d1n4dlla

Property	Value
?:abstract	OBJECTIVES: To evaluate the impact of low molecular weight heparin (LMWH) on the outcome of patients with SARS-CoV-2 pneumonia. METHODS: Prospective observational study including consecutive patients with laboratory confirmed SARS-CoV-2 pneumonia admitted to the University Hospital of Pisa (4th March-30(th) April 2020). Demographic, clinical, and outcome data were collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe ARDS. LMWH, hydroxychloroquine, doxycycline, macrolides, antiretrovirals, remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox-regression analysis, in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent Propensity-score (PS) was calculated and a PS-matching performed for each treatment variable. RESULTS: Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) hydroxychloroquine, 201 (63.8%) proteases inhibitors, 150 (47.6%) doxycycline, 141 (44.8%) steroids, 42 (13.3%) macrolides, 40 (12.7%) baricitinib, 13 (4.1%) tocilizumab, and 13 (4.1%) remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (HR 0.36 [95% CI 0.21-0.6], p<0.001) and composite endpoint (HR 0.61 [95% CI 0.39-0.95], p=0.029). The PS-matched cohort of 55 couples confirmed the same results for both primary and secondary endpoint. CONCLUSIONS: This study suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in Covid-19. Randomized controlled trials are warranted to confirm these preliminary findings.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/d1n4dlla_hasAnnotation_C0033607> <https://research.tib.eu/covid-19/entity/d1n4dlla_hasAnnotation_C0274281> <https://research.tib.eu/covid-19/entity/d1n4dlla_hasAnnotation_C0599685> <https://research.tib.eu/covid-19/entity/d1n4dlla_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/d1n4dlla_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Falcone%2C_Marco%3B_Tiseo%2C_Giusy%3B_Barbieri%2C_Greta%3B_Galfo%2C_Valentina%3B_Russo%2C_Alessandro%3B_Virdis%2C_Agostino%3B_Forfori%2C_Francesco%3B_Corradi%2C_Francesco%3B_Guarracino%2C_Fabio%3B_Carrozzi%2C_Laura%3B_Celi%2C_Alessandro%3B_Santini%2C_Massimo%3B_Monzani%2C_Fabio%3B_De_Marco%2C_Salvatore%3B_Pistello%2C_Mauro%3B_Danesi%2C_Romano%3B_Ghiadoni%2C_Lorenzo%3B_Alessio%2C_Farcomeni%3B_Menichetti%2C_Francesco>
?:doi	<https://research.tib.eu/covid-19/entity/10.1093/ofid/ofaa563>
?:doi	10.1093/ofid/ofaa563
?:journal	Open_Forum_Infect_Dis
?:license	cc-by-nc-nd
?:pdf_json_files	document_parses/pdf_json/e91718005de7b6b0aa0e00ac94677737ed32bfc2.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7717381>
?:pmid	<https://research.tib.eu/covid-19/entity/33365358.0>
?:pmid	33365358.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/d1n4dlla_HAS_C0035222_COEXISTS_WITH_C5203670>
?:sha_id	<https://research.tib.eu/covid-19/entity/e91718005de7b6b0aa0e00ac94677737ed32bfc2>
?:source	Medline; PMC
?:title	Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-19

Property

Value

?:abstract

OBJECTIVES: To evaluate the impact of low molecular weight heparin (LMWH) on the outcome of patients with SARS-CoV-2 pneumonia. METHODS: Prospective observational study including consecutive patients with laboratory confirmed SARS-CoV-2 pneumonia admitted to the University Hospital of Pisa (4th March-30(th) April 2020). Demographic, clinical, and outcome data were collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe ARDS. LMWH, hydroxychloroquine, doxycycline, macrolides, antiretrovirals, remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox-regression analysis, in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent Propensity-score (PS) was calculated and a PS-matching performed for each treatment variable. RESULTS: Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) hydroxychloroquine, 201 (63.8%) proteases inhibitors, 150 (47.6%) doxycycline, 141 (44.8%) steroids, 42 (13.3%) macrolides, 40 (12.7%) baricitinib, 13 (4.1%) tocilizumab, and 13 (4.1%) remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (HR 0.36 [95% CI 0.21-0.6], p<0.001) and composite endpoint (HR 0.61 [95% CI 0.39-0.95], p=0.029). The PS-matched cohort of 55 couples confirmed the same results for both primary and secondary endpoint. CONCLUSIONS: This study suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in Covid-19. Randomized controlled trials are warranted to confirm these preliminary findings.

is ?:annotates of